tbuckley/cabot-search huggingface dataset:
Cardiac output and regional flow in health and disease: Edited by A-M Salmasi and AS Iskandrian. (Pp 575; 140.) Dordrecht: Kluwer, 1992. ISBN 0-7923-1911-7
Authors: J Rawles
Journal: Cardiovascular Research (1995)

Cardiac output and regional flow in health and disease: Edited by A-M Salmasi and AS Iskandrian. (Pp 575; £140.) Dordrecht: Kluwer, 1992. ISBN 0-7923-1911-7 Cardiac Output and Regional Flow in Health and Disease. Edited by Salmasi A-M Iskandrian A S. (Pp 575; £140.) Dordrecht: Kluwer, 1992. ISBN 0-7923-1911-7. J Rawles J Rawles Aberdeen, UK Search for other works by this author on: Oxford Academic PubMed Google Scholar Cardiovascular Research, Volume 29, Issue 1, January 1995, Page 144, https://doi.org/10.1016/S0008-6363(95)90119-1 Published: 01 January 1995
Abstract SY20-01: Conventional chemotherapy cures people by exploiting apoptotic priming
Authors: Anthony G. Letai
Journal: Cancer Research (2015)

Abstract Conventional chemotherapy has an amazing track record that is often under-appreciated in today's world of genomics and targeted pathway inhibitors. Conventional chemotherapy is responsible for curing millions of cancer patients over the past 5 decades. That is, millions of patients have presented to their doctors with an otherwise fatal malignancy, were given a finite course of chemotherapy (largely DNA and microtubule perturbing agents) and had their cancer eradicated, never to return. Perhaps as remarkable as the magnitude of the achievement of conventional chemotherapy is the magnitude of our ignorance of why it should ever work, and why it works far better in some tumors than in others. Textbook explanations rely on concepts of differential proliferation rates in cancers that are incompletely supported in the clinical literature. Successful chemotherapy treatments usually kill via the mitochondrial pathway of apoptosis. We have found that simple functional measurements of the pre-treatment state of the tumor cell can be rapidly made with BH3 profiling. These measurements demonstrate that a major, if not the major, reason for a therapeutic index for cancer chemotherapy is that chemo-sensitive cancer cells are simply more primed for apoptosis than normal cells. Moreover, apoptotic priming can be measured to make clinical predictions regarding quality of response on an individualized basis. Enhancing pretreatment priming of cancer cells with selectively acting targeted agents is a promising strategy to extend the demonstrated curative power of conventional chemotherapy. Citation Format: Anthony G. Letai. Conventional chemotherapy cures people by exploiting apoptotic priming. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr SY20-01. doi:10.1158/1538-7445.AM2015-SY20-01
Hematologic Improvement with Iron Chelation using therapy Deferasirox in Patients with Aplastic Anemia: A Subgroup Analysis of KAMS0112 Prospective Study,
Authors: Yoo-Hong Min, Sung-Soo Yoon, Hyeoung Joon Kim, Kyoo-Hyung Lee, Jae Hoon Lee, Jong Ho Won, Jae Yong Cho, Hyeok Shim, Ho Young Kim, Chu-Myung Seung, Chul Soo Kim, Mark Hong Lee, Jooseop Chung, Myung Soo Hyun, Deog-Yeon Jo, Chul Won Jung, Sang Kyun Sohn, Hwi-Joong Yoon, Byung Soo Kim, Young-Don Joo, June-Won Cheong
Journal: Blood (2011)
Identification of Clonal Igh Gene Rearrangements By High-Throughput Sequencing of Cell Free DNA in Multiple Myeloma Patients
Authors: Silvia Gimondi, Alessandra Cavanè, Antonio Vendramin, Biancon Giulia, Anisa Bermema, Vittorio Montefusco, Paolo Corradini, Cristiana Carniti
Journal: Blood (2015)
A randomized double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic cancer (mPC).
Authors: Herbert Hurwitz, Nikhil Uppal, Stephanie Ann Wagner, Johanna C. Bendell, J. Thaddeus Beck, Seaborn Wade, John J. Nemunaitis, Philip J. Stella, J. Marc Pipas, Zev A. Wainberg, Robert Manges, William M. Garrett, Deborah S. Hunter, Jason Clark, Lance Leopold, Richard S. Levy, Victor Sandor
Journal: Journal of Clinical Oncology (2014)

4000 Background: Local and systemic inflammation (INFL) are hallmarks of cancer, including PC, that adversely impact prognosis. Given the role of JAK-STAT signaling in cancer INFL, the efficacy and safety of RUX, a JAK1/JAK2 inhibitor, given with CAPE in pts with mPC refractory to initial therapy was explored. Methods: Pts with adequate performance status and organ function who progressed after gemcitabine treatment were included. RUX + CAPE was well tolerated in a 9 pt safety run-in. Subsequently, 127 pts were randomized to CAPE 1000 mg/m2 BID days 1–14 with either RUX 15 mg BID or PBO on days 1–21 of a 21-day cycle. The primary endpoint was OS; secondary endpoints included PFS and ORR. To detect a HR ≤0.6 with 2-sided α=0.2 and β<0.2, final analysis was planned to occur after 97 deaths. Subgroup analyses were prespecified to explore treatment heterogeneity and a hypothesis that RUX would preferentially benefit pts with evidence of INFL. Results: In the randomized population, OS and PFS favored RUX (Table). Confirmed ORR was 7.8% for RUX and 0% for PBO. In a prespecified subgroup of pts with INFL, as measured by serum C-reactive protein (CRP > group median of 13 mg/L), OS significantly favored RUX over PBO (Table). In this subgroup, 3 and 6 month survival was 48% and 42% with RUX vs 29% and 11% with PBO, respectively. In pts with CRP ≤13 mg/L, significant benefits in OS or PFS were not observed (HR = 0.89 and 0.82, respectively). OS benefit was also seen in pts classified by modified Glasgow Prognostic Score (mGPS), a measure of INFL in cancer (HRs 0.91, 0.71, 0.49 for mGPS 0, 1, 2, respectively). The combination of RUX and CAPE was generally well tolerated. Grade 3 or 4 (G3/4) adverse events occurred in 75% and 82% of RUX and PBO pts, respectively. G3/4 neutropenia and thrombocytopenia were uncommon in RUX pts (1.7% and 0%, respectively). G3/4 anemia occurred more frequently on RUX (15.3%) than PBO (1.7%). Conclusions: RUX may improve OS and PFS in mPC pts with INFL characterized by elevated CRP or mGPS of 1 or 2. Clinical trial information: NCT01423604. HR (95% CI) RUX PBO Randomized, n 64 63 OS 0.79 (0.53–1.18) p=0.25 PFS 0.75 (0.52–1.10) p=0.28 CRP >13 mg/L, n 31 29 OS 0.47 (0.26–0.85) p=0.01 PFS 0.62 (0.35–1.1) p=0.20
Chemotherapy Effects on Natural Killer Cells in Children with Acute Lymphoblastic Leukemia
Authors: Tugce Aksu Uzunhan, Zeynep Karakas, Serap Erdem Kuruca, Sabriye Karadenizli, Beyza Cetin, Nilgun Akdeniz, Gunnur Deniz, Omer Devecioglu
Journal: Blood (2010)
DAI Senses Influenza A Virus Genomic RNA and Activates RIPK3-Dependent Cell Death
Authors: Roshan J. Thapa, Justin P. Ingram, Katherine B. Ragan, Shoko Nogusa, David F. Boyd, Asiel A. Benitez, Haripriya Sridharan, Rachelle Kosoff, Maria Shubina, Vanessa J. Landsteiner, Mark Andrake, Peter Vogel, Luis J. Sigal, Benjamin R. tenOever, Paul G. Thomas, Jason W. Upton, Siddharth Balachandran
Journal: Cell Host & Microbe (2016)
Patterns and Trends in Age-Specific Black-White Differences in Breast Cancer Incidence and Mortality – United States, 1999–2014
Authors: Lisa C. Richardson, S. Jane Henley, Jacqueline W. Miller, Greta Massetti, Cheryll C. Thomas
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

Breast cancer continues to be the most commonly diagnosed cancer and the second leading cause of cancer deaths among U.S. women (1). Compared with white women, black women historically have had lower rates of breast cancer incidence and, beginning in the 1980s, higher death rates (1). This report examines age-specific black-white disparities in breast cancer incidence during 1999-2013 and mortality during 2000-2014 in the United States using data from United States Cancer Statistics (USCS) (2). Overall rates of breast cancer incidence were similar, but death rates remained higher for black women compared with white women. During 1999-2013, breast cancer incidence decreased among white women but increased slightly among black women resulting in a similar average incidence at the end of the period. Breast cancer incidence trends differed by race and age, particularly from 1999 to 2004-2005, when rates decreased only among white women aged ≥50 years. Breast cancer death rates decreased significantly during 2000-2014, regardless of age with patterns varying by race. For women aged ≥50 years, death rates declined significantly faster among white women compared with black women; among women aged <50 years, breast cancer death rates decreased at the same rate among black and white women. Although some of molecular factors that lead to more aggressive breast cancer are known, a fuller understanding of the exact mechanisms might lead to more tailored interventions that could decrease mortality disparities. When combined with population-based approaches to increase knowledge of family history of cancer, increase physical activity, promote a healthy diet to maintain a healthy bodyweight, and increase screening for breast cancer, targeted treatment interventions could reduce racial disparities in breast cancer.
Quality indicators of continuous renal replacement therapy (CRRT) care in critically ill patients: a systematic review
Authors: Oleksa G. Rewa, Pierre-Marc Villeneuve, Philippe Lachance, Dean T. Eurich, Henry T. Stelfox, R. T. Noel Gibney, Lisa Hartling, Robin Featherstone, Sean M. Bagshaw
Journal: Intensive Care Medicine (2016)
Effect of An Omega-3 Polyunsaturated Fatty Acid Enriched Diet, Acetylsalicylic Acid, and Aspirin-Triggered Lipoxin on Survival in a Murine Model of Acute Graft-Versus-Host Disease
Authors: Geoff D. E. Cuvelier, Yuri V Lissitsyn, Mohammed H Moghadasian, Khuong Le, Cynthia A Ellison
Journal: Blood (2011)
Phase II Study of All-Trans Retinoic Acid (ATRA), Arsenic Trioxide (ATO), with or without Gemtuzumab OzogamIcin (GO) for the Frontline Therapy of Patients with Acute Promyelocytic Leukemia (APL).
Authors: Farhad Ravandi, Elihu H. Estey, Jorge E. Cortes, Susan O'Brien, Sherry A. Pierce, Mark Brandt, Alessandra Ferrajoli, Gautam Borthakur, Marina Konopleva, Srdan Verstovsek, Guillermo Garcia-Manero, Stefan Faderl, Hagop Kantarjian
Journal: Blood (2010)
TCT-485 Effect of Gender on Clinical Outcomes in Patients With or Without Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Results from a Large Single Center Registry
Authors: Gennaro Giustino, Robert Saporito, Usman Baber, Melissa Aquino, George Dangas, Jason Kovacic, Pedro R. Moreno, Swathi Roy, Prakash Krishnan, Joe Sweeny, Roxana Mehran, Annapoorna Kini, Samin K. Sharma
Journal: Journal of the American College of Cardiology (2015)
The Department of Veterans Affairs Nutritional Status Classification Scheme Allows for Rapid Assessment of Nutritional Status Before Autologous Peripheral Blood Stem Cell Transplantation and Identifies Patients at High-Risk of Transplant-Related Complications
Authors: Juan J. Toro, David J. Haile, Ju-Hsien Chao, Pamela S. Jewell, Shuko Lee, Cesar O. Freytes
Journal: Blood (2008)
Investigation Of The Genetic Disparities Between African Americans and Causasians Utilizing Gene Expression Profiles (GEP) Of Purified Plasma Cells (PC) and Whole Bone Marrow Biopsies (BMBx)
Authors: Adam Rosenthal, Christoph Heuck, Aziz Bakhous, Frits van Rhee, Antje Hoering, Sarah Waheed, Nathan M Petty, Clyde Bailey, Donald Johann, Joshua Epstein, John Crowley, Bart Barlogie
Journal: Blood (2013)
ON THE MECHANISM OF OPSONIN AND BACTERIOTROPIN ACTION
Authors: Stuart Mudd, Balduin Lucké, Morton McCutcheon, Max Strumia
Journal: The Journal of Experimental Medicine (1929)

Methods are described for investigating the relation between phagocytosis of bacteria by polymorphonuclear leucocytes, and certain physical-chemical properties of the bacterial surface. Serum sensitization causes the following changes in the properties of acid-fast bacteria: (a) increased cohesiveness, (b) decrease in surface electric potential difference, (c) decrease in wettability of the bacteria by oil, and (d) increased phagocytosis. Tests have been conducted periodically with the sera of 4 rabbits under active immunization with as many strains of acid-fast bacteria; the parallelism between the alteration in bacterial surface properties and the promotion of phagocytosis by these sera has been, within the experimental error, complete. The percentage of phagocytosis of a given bacterial suspension has been found to depend both upon the sensitizing serum component or components deposited upon the bacterium and upon the intrinsic properties of the unsensitized bacterial surface.
Effect of vaccination of leukemia patients with a MHC class I peptide of Wilms tumor gene 1 (WT1) peptide with unspecific T helper stimulation on WT1-specific IgM responses and on IgG responses
Authors: A. Letsch, O. Elisseeva, C. Scheibenbogen, A. Asemissen, D. Stather, A. Busse, Y. Oka, U. Keilholz, H. Sugiyama, E. Thiel
Journal: Journal of Clinical Oncology (2008)

3054 Background: To assess the humoral responses in AML and MDS patients vaccinated with an HLA-A2-restricted class I binding WT1 peptide within a phase II trial. Methods: 14 patients vaccinated with 0.2 mg WT1.126–134 peptide together with adjuvants KLH and GM-CSF days 1–4 were analyzed for humoral and cellular responses to WT1. Vaccination was repeated biweekly x 12 and monthly afterwards until progression. Baseline antibody responses were determined in all patients and during vaccination at week 10 (n=8), week 18 (n=7) and weeks 26 or 30 (n=6). WT1-specific CD8+T cell responses were analyzed by tetramer staining at baseline, at week 10 (n=13) and week 18 (n= 10). Results: In 2 of the 14 patients spontaneous WT1-specific IgM responses could be detected before vaccination. Likewise, spontaneous IgG responses against WT1 were recorded in 3 of 14 patients. Enhanced WT1 IgM antibodies were detected in 3 of 7 patients at week 18 and in 6 of 6 patients at weeks 26 or 30, but never earlier (week 10). In contrast, WT1-specific CD8 T cell responses peaked already at week 10. CD4+ T cell responses could not be detected against the vaccine peptide and no IgG antibody responses could be induced or enhanced by vaccination. Conclusions: Long-term vaccination with an HLA-A2/MHC class I- restricted peptide was able to induce WT1-specific IgM antibodies. The failure to induce IgG antibodies gave evidence that due to the lack of a specific T helper cell epitope in this vaccine no isotype switch of B cells occurred. No significant financial relationships to disclose.
TCT-63 One Year Results Of The REMEDEE Registry: Clinical Outcomes After Deployment Of The Abluminal Sirolimus Coated Bio-Engineerd Stent In A Multicenter, Prospective Post Market Registry
Authors: Robbert J. de Winter, Peter den Heijer, Ian Menown, Andrejs Erglis, Harry Suryapranata, Karin Arkenbout, Andres Iñiguez Romo, Arnoud van 't Hof, Philippe Muller, Pier Woudstra, Deborah N. Kalkman, Jan G. Tijssen
Journal: Journal of the American College of Cardiology (2015)
Evaluation of Variability in Inhaled Nitric Oxide Use and Pulmonary Hypertension in Patients With Congenital Diaphragmatic Hernia
Authors: Luke R. Putnam, Kuojen Tsao, Francesco Morini, Pamela A. Lally, Charles C. Miller, Kevin P. Lally, Matthew T. Harting
Journal: JAMA Pediatrics (2016)

Inhaled nitric oxide (iNO) is an expensive, commonly used therapy among patients with congenital diaphragmatic hernia (CDH); however, data to support its ongoing use in this patient population are lacking.To describe the spectrum of iNO use among patients with CDH and its association with pulmonary hypertension (pHTN) and mortality.A review was conducted of prospectively collected patient data in the Congenital Diaphragmatic Hernia Study Group registry between January 1, 2007, and December 31, 2014, from 70 participating centers in 13 countries. A total of 3367 newborn infants diagnosed with CDH and entered into the registry were reviewed. On the basis of echocardiogram data, pHTN was defined as right ventricular systolic pressure greater than or equal to two-thirds of the systemic systolic pressure. Propensity score and regression analyses were performed.Use of iNO.Variability in iNO use and its association with pHTN and mortality. These outcomes were formulated prior to data evaluation.Sixty-eight (97.1%) centers used iNO. Of 3367 patients with CDH (1366 [40.6%] females; median estimated gestational age, 38 weeks; range, 23-42 weeks), a total of 2047 (60.8%) received iNO; the mean percentage of those receiving iNO per center was 62.3% (range, 0%-100%). Median iNO dose and duration were 20 (range, 0.1-80) ppm and 8 (range, 0-100) days. Of the 2174 infants with pHTN, 1613 infants (74.2%) received iNO. Of the 943 infants without pHTN, 343 infants (36.4%) were treated with iNO. Based on propensity score analysis incorporating 10 clinically relevant variables, iNO use was significantly associated with increased mortality (average treatment effect on the treated: 0.15; 95% CI, 0.10-0.20).Inhaled nitric oxide use is common but highly variable among centers, and 36% of patients without pHTN received iNO therapy. Based on data from 70 centers, iNO use in patients with CDH may be associated with increased mortality. Future efforts should be directed toward data-driven standardization of iNO use to ensure cost-effective practices.
TCT-596 Dose Dependent Vascular Response Following Delivery Of Sirolimus Via Fast Releasing, Biodegradable Polymer Stent Matrix: An Experimental Study In The Porcine Coronary Model Of Restenosis
Authors: Piotr P. Buszman, Bartłomiej Orlik, Jacek Pajak, Michal Jelonek, Agata Krauze, Adam Janas, Jacek Legutko, Buszman E. Pawel, Krzysztof P. Milewski
Journal: Journal of the American College of Cardiology (2015)
Trust plans to ask pregnant women for photo ID before accessing maternity services
Authors: Ingrid Torjesen
Journal: BMJ (2016)

All pregnant women wanting to book in for maternity services at St George’s University Hospitals NHS Foundation Trust will have to produce proof of their eligibility for free NHS care under a pilot scheme planned by the financially challenged trust. If the pilot study is successful it will be rolled out to other services across the hospital.

The scheme, outlined in the trust’s October board papers, would require women to produce photo ID, such as a passport or proof of their right to remain in the UK (visa, proof of asylum status), and a current utility bill, before receiving care.1 Any woman not able to prove eligibility would be referred to the Overseas Patient Team for further investigation.

Patients are currently asked to complete a booking-in form that requests proof of eligibility, including passport details. But in practice patients rarely complete these details and are later sent a letter asking them to provide documentation to prove eligibility. If patients do not …
Targeted Next-Generation Sequencing (NGS) Enables a Broad Screening of 95 Molecular Mutations In a One-Step Approach and Detects Recurrent Mutations In AML with a Normal Karyotype In MYH11 and NOTCH1
Authors: Alexander Kohlmann, Vera Grossmann, Hans-Ulrich Klein, Susanne Schnittger, Martin Dugas, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach
Journal: Blood (2010)
Salvage of Primary Refractory Acute Leukemia (AL) with High-Dose Etoposide (VP) and Cyclophosphamide (CY) Followed by Early Stem Cell Transplantation (SCT): An Effective Treatment Strategy for AML but Not for All.
Authors: Thomas J. Nevill, Asha Johny, Kevin W. Song, Julye C. Lavoie, Cynthia L. Toze, Michael J. Barnett, Donna E. Hogge, John D. Shepherd, Janet Y. Nita, Alan Le, Heather J. Sutherland, Clayton A. Smith, Donna L. Forrest, Stephen H. Nantel
Journal: Blood (2004)
TCT-1 High number of angiographic significant lesions are FFR negative in STEMI patients with multi-vessel disease: preliminary insight into the COMPARE-ACUTE trial
Authors: Pieter C. Smits, Ketil Lunde, Elmir Omerovic, Carl E. Schotborgh, Gert Richardt, Mohamed Abdel-Wahab, Franz-Josef Neumann, Paul Ong, Rainer Hambrecht, Adrian Wlodarczak, Petr Kala, Zsolt Piroth, Peter W. Danse, Bianca M. Boxma-de Klerk, Georgios J. Vlachojannis
Journal: Journal of the American College of Cardiology (2015)
Phase II study of bevacizumab and erlotinib in treatment-naïve elderly patients (older than age 65) with advanced non-small cell lung cancer (NSCLC).
Authors: H. Borghaei, R. Mehra, M. M. Millenson, H. Tuttle, K. Ruth, A. J. Magdalinski, D. M. Mintzer, J. W. Lee, G. R. Simon, C. J. Langer
Journal: Journal of Clinical Oncology (2010)

e18019 Background: The median age of newly diagnosed NSCLC patients (pts) in the United States is 71 and hence more than 60% of the pts will be 65 years of age or older. However, the elderly are under represented in clinical trials. The ‘fit elderly' (PS 0-1) derive the same level of benefit from systemic therapy as others but with a lower tolerance for toxicities. Innovative treatment strategies with less toxicity are, therefore, needed. This study explores the efficacy and tolerability of an ‘all-biologic' therapy in treatment-naïve elderly pts with advanced NSCLC. Methods: Fit elderly pts (≥70 years of age) with treatment-naïve stage IV or IIIB (malignant pleural effusion [MPE]) were treated with full dose erlotinib (150 mg/d) and bevacizumab (15 mg/kg Q 3 ks) in 21 day cycles. Progression Free Survival (PFS) was the primary endpoint. EGFR status was not required for enrollment. Imaging was performed every 2 cycles. Attributable grade 3 and 4 adverse events (AEs) were documented. Results: To date, 24 evaluable pts have been enrolled. Median age is 75 (range: 70-84). Fifteen pts (63%) have ECOG PS of 1. Five pts have stage IIIB disease. Kaplan-Meier estimate of median time from starting therapy to going off protocol is 4.8 months (95% confidence interval = 1.9-6.7). Of the 17 pts now off protocol, the median number of cycles is 4 (range: 1-23). Seven pts are currently on protocol, (range 3 to 38 cycles). For the first 15 pts on study, drug-related grade 3 (G3) and 4 (G4) AEs include hypertension (G3: 3 pts), fatigue (G3: 1 pt), rash (G3: 3 pts), diarrhea (1 G3 and 1 G4), anorexia (G3: 1 pt), and infection with neutropenia (G3: 1 pt). Five pts had partial response, four confirmed. Eleven pts had stable disease, four had progressive disease, and one was not evaluated. The response status of three pts is still pending. The estimated median PFS for all patients is 6.4 months (95% confidence interval 3.6-14.9 months). The estimated one year OS is 63.9% (95% CI = 33.6%-83.2%). Median OS has not been reached. Conclusions: Our data suggest that an all biologic combination with erlotinib and bevacizumab appears to be effective and well tolerated for the first-line management of elderly patients with advanced NSCLC. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration GlaxoSmithKline Genentech/OSI, Pfizer Genentech/OSI Genentech/OSI
CSF1R Inhibition by PLX3397 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Results From a Phase 2 Single Agent Clinical Trial
Authors: Craig H. Moskowitz, Anas Younes, Sven de Vos, R. Gregory Bociek, Leo I. Gordon, Thomas E. Witzig, Randy D. Gascoyne, Brian West, Keith Nolop, Christian Steidl
Journal: Blood (2012)
Infusion of Large Number of Circulating Myeloma Cells Does Not Influence the Survival of Patients Undergoing Autologous Stem Cell Transplantation.
Authors: Rafat Abonour, Hayley Knollman, Attaya Suvannasankha, Menggang Yu, Rebecca Britton, Shivani Srivastava, Robert P. Nelson, Jennifer E. Schwartz, Michael Robertson, Kenneth Cornetta, Sherif Farag
Journal: Blood (2009)
TCT-520 Real-world Clinical Outcomes of Bioresorbable Vascular Scaffold Versus Conventional Drug Eluting Stents in Primary-PCI for ST-elevation Myocardial Infarction: single center one-year experience
Authors: Quentin de Hemptinne, Philippe L. L'Allier, Marc E. Jolicoeur, Hung Ly, Jean-François Tanguay
Journal: Journal of the American College of Cardiology (2015)